A Practical Perspective on the Use of Botanicals During the COVID-19 Pandemic: From Proven to Potential Interactions

Alexander Bertuccioli, Marco Cardinali, Francesco Di Pierro, Simone Magi, Giordano Zonzini, Alexander Bertuccioli, Marco Cardinali, Francesco Di Pierro, Simone Magi, Giordano Zonzini

Abstract

In this review, we examined the top 10 nutraceutical products sold in Italian pharmacies and parapharmacies as well as hypermarkets and supermarkets; in the first, three product categories saw the greatest increase in sales (vitamins and minerals, immunostimulants, and sleep products) for the 12-month period between October 2019 and October 2020 (including first pandemic wave of SARS-CoV-2). We are investigating their respective formulas and isolating the botanicals that are used to make them. Many of these products have undergone preclinical and clinical studies. We performed a systematic literature search in the MEDLINE database using PubMed and Google Scholar from November 15, 2020 to December 15, 2020 (including studies carried out between 1980 and 2020). The search terms that were used included the complete name of the medicinal plant in English or Latin and the terms "cytochrome" or "drug interactions," crossing, respectively, the Latin name and English common names with "cytochrome" and "drug interactions." The search included in vitro and in vivo studies describing the effects of interaction between the plant (extract or botanical medicine) and human cytochromes. Despite their great complexity, there is decidedly limited clinical data on botanical medicine. In fact, of the 28 botanicals that were examined, only 2 (Citrus paradisi and Rhodiola rosea) show in vivo pharmacological interactions in human subjects. On the contrary, for the other botanicals, there is only weak evidence of dubious clinical significance or potential interactions shown in animal models or in vitro without clinical confirmation. This study provides a rational assessment of the most widely used products, including those used in self-medication, to simplify patient management during the COVID-19 health emergency.

Keywords: COVID-19; CYP; SARS-CoV-2; botanicals; cytochrome; nutraceuticals.

Conflict of interest statement

No competing financial interests exist.

References

    1. Gualano MR, Lo Moro G, Voglino G, Bert F, Siliquini R: Effects of Covid-19 lockdown on mental health and sleep disturbances in Italy. Int J Environ Res Public Health 2020;17:4779.
    1. The supplement market. Drivers and purchasing dynamics in times of COVID [in Italian] (accessed January 1, 2021).
    1. IQVIA Institute for Human Data Science Reports - commerce data tracking October 2020. . (accessed January 1, 2021).
    1. World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. World Health Organization, Geneva, 2019.
    1. Danielson PB: The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3:561–597.
    1. Guengerich FP: Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1–17.
    1. Etheridge AS, Black SR, Patel PR, So J, Mathews JM: An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007;73:731–741.
    1. Feltrin C, Farias IV, Sandjo LP, Reginatto FH, Simões CMO: Effects of standardized medicinal plant extracts on drug metabolism mediated by CYP3A4 and CYP2D6 enzymes. Chem Res Toxicol 2020;33:2408–2419.
    1. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK: Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755–763.
    1. Hermann R, von Richter O: Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78:1458–1477.
    1. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW: Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35–98.
    1. He SM, Chan E, Zhou SF: ADME properties of herbal medicines in humans: Evidence, challenges and strategies. Curr Pharm Des 2011;17:357–407.
    1. Suroowan S, Mahomoodally MF: Herbal medicine of the 21st century: A focus on the chemistry, pharmacokinetics and toxicity of five widely advocated phytotherapies. Curr Top Med Chem 2019;19:2718–2738.
    1. Ulbricht C, Basch E, Weissner W, Hackman D: An evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration. Expert Opin Drug Saf 2006;5:719–728.
    1. Kennedy DA, Seely D: Clinically based evidence of drug–herb interactions: A systematic review. Expert Opin Drug Saf 2009;9:79–124.
    1. Shord SS, Shah K, Lukose A: Drug-botanical interactions: A review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009;8:208–227.
    1. Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: An updated systematic review. Drugs 2009;69:1777–1798.
    1. Mukherjee PK, Ponnusankar S, Pandit S, Hazam PK, Ahmmed M, Mukherjee K: Botanicals as medicinal food and their effects on drug metabolizing enzymes. Food Chem Toxicol 2011;49:3142–3153.
    1. Gurley B: Pharmacokinetic herb-drug interactions (part 1): Origins, mechanisms, and the impact of botanical dietary supplements. Planta Med 2012;78:1478–1489.
    1. Gurley B, Fifer E, Gardner Z: Pharmacokinetic herb-drug interactions (part 2): Drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 2012;78:1490–1514.
    1. Wanwimolruk S, Prachayasittikul V: Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J 2014;13:347–391.
    1. Wanwimolruk S, Phopin K, Prachayasittikul V: Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). EXCLI J 2014;13:869–896.
    1. Cho HJ, Yoon IS: Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein. Evid Based Complement Alternat Med 2015;2015:736431.
    1. Bano G, Amla V, Raina RK, Zutshi U, Chopra CL: The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987;53:568–569.
    1. World Health Organization: WHO Monographs on Selected Medicinal Plants vol 1–4. World Health Organization, Geneva, 1999–2009. Italian Phytotherapy Society (SIFIT) Edition 2002–2017.
    1. Frank A, Unger M: Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006;1112:255–262.
    1. Heber D: PDR (Physicians Desk Reference) for Herbal Medicine, 4th ed. Thomson Healthcare, Inc., New Jersey, United States, 2007.
    1. Albassam AA, Markowitz JS: An appraisal of drug-drug interactions with green tea (Camellia sinensis). Planta Med 2017;83:496–508.
    1. Oga EF, Sekine S, Shitara Y, Horie T: Pharmacokinetic herb-drug interactions: insight into mechanisms and consequences. Eur J Drug Metab Pharmacokinet 2016;41:93–108.
    1. Hidaka M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K: Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004;32:581–583.
    1. Chatuphonprasert W, Jarukamjorn K: Impact of six fruits—Banana, guava, mangosteen, pineapple, ripe mango and ripe papaya—On murine hepatic cytochrome P450 activities. J Appl Toxicol 2012;32:994–1001.
    1. Nutescu EA, Shapiro NL, Ibrahim S, West P: Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006;5:433–451.
    1. Jia Y, Zou J, Wang Y, Zhang X, Shi Y, Liang Y, Guo D, Yang M: Action mechanism of Roman chamomile in the treatment of anxiety disorder based on network pharmacology. J Food Biochem 2021;45:e13547.
    1. Srivastava JK, Shankar E, Gupta S: Chamomile: A herbal medicine of the past with bright future. Mol Med Rep 2010;3:895–901.
    1. Malhotra S, Bailey DG, Paine MF, Watkins PB: Seville orange juice-felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14–23.
    1. Zhou L, Man C, Linlin Z, Dongsheng W, Tao T, Wenbo W, Sheng W, Huiyong H, Xinjian Q: Potential metabolic drug–drug interaction of Citrus aurantium L. (Rutaceae) evaluating by its effect on 3 CYP450. Front Pharmacol 2018;9:895.
    1. Khalil MNA, Farghal HH, Farag MA: Outgoing and potential trends of composition, health benefits, juice production and waste management of the multi-faceted Grapefruit Citrus Χ paradisi: A comprehensive review for maximizing its value. Crit Rev Food Sci Nutr 2020:1–22. [Epub ahead of print]; DOI: 10.1080/10408398.2020.1830364.
    1. Cristóbal-Luna JM, Álvarez-González I, Madrigal-Bujaidar E, Chamorro-Cevallos G: Grapefruit and its biomedical, antigenotoxic and chemopreventive properties. Food Chem Toxicol 2018;112:224–234.
    1. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR: Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468–477.
    1. Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP: Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 2004;76:607–617.
    1. Ho PC, Saville DJ, Wanwimolruk S: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001;4:217–227.
    1. Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, Niemi M, Backman JT: Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol 2013;75:1488–1496.
    1. Lin HL, Kenaan C, Hollenberg PF: Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos 2012;40:998–1006.
    1. Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V: Grapefruit-drug interactions: Can interactions with drugs be avoided? J Clin Pharmacol 2006;46:1390–1416.
    1. Paine MF, Criss AB, Watkins PB: Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005;312:1151–1160.
    1. Brandin H, Myrberg O, Rundlöf T, Arvidsson AK, Brenning G: Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy. Eur J Clin Pharmacol 2007;63:565–570.
    1. Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaronson KD, Bleske BE: Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003;43:637–642.
    1. Freeman C, Spelman K: A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res 2008;52:789–798.
    1. Budzinski W, Foster BC, Vandenhoek' S: Amason an in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273–282.
    1. Mrozikiewicz PM, Bogacz A, Karasiewicz M, Mikolajczak PL, Ozarowski M, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozlowska T, Grzeskowiak E: The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine 2010;17:830–833.
    1. Yale SH, Glurich I: Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005;11:433–439.
    1. Hu Z, Yang Z, Ho P, Chan SY, Heng PWS, Chan E, Duan E, Koh HL, Zhou S: Herb-drug interactions. Drugs 2005;65:1239–1282.
    1. Donovan JL, DeVane CL, Chavin DL, Taylor RM, J Markowitz JS: Siberian Ginseng (Eleutheroccus senticosus) effects On CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003;31:519–522.
    1. Manda VK, Ibrahim MA, Dale OR, Kumarihamy M, Cutler SJ, Khan IA, Larry AW, Muhammad, Khan SI: Modulation of CYPs, P‑gp, and PXR by Eschscholzia californica (California Poppy) and its alkaloids. Planta Med 2016;82:551–558.
    1. Guida alle piante fitoterapiche [in Italian] (from CODIFA database) 2019 EDRA edition.
    1. Nosková K, Dovrtělová G, Zendulka O, Řemínek R, Juřica J: The effect of (-)-linalool on the metabolic activity of liver CYP enzymes in rats. Physiol Res 2016;65(Suppl 4):S499–S504.
    1. Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schläfke S, Dienel A, Gramatté T, Lück H, Fuhr U: Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 2013;41:987–993.
    1. Tang D, Chen K, Huang L, Li J: Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin Drug Metab Toxicol 2017;13:323–330.
    1. Ganzera M, Schneider P, Stuppner H: Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sci 2006;78:856–861.
    1. Colombo D, Lunardon L, Bellia G: Cyclosporine and herbal supplement interactions. J Toxicol 2014;2014:145325.
    1. Meesters RJ, Duisken M, Hollender J: Cytochrome P450-catalysed arene-epoxidation of the bioactive tea tree oil ingredient p-cymene: Indication for the formation of a reactive allergenic intermediate? Xenobiotica 2009;39:663–671.
    1. Kumar D, Trivedi N, Dixit RK: Evaluation of the synergistic effect of Allium sativum, Eugenia jambolana, Momordica charantia, Ocimum sanctum, and Psidium guajava on hepatic and intestinal drug metabolizing enzymes in rats. J Intercult Ethnopharmacol 2016;5:372–382.
    1. Stupansa I, Murrayb A, Kirlicha A, Tucka KL, Hayballa PJ: Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol 2001;39:1119–1124.
    1. Zhoua G, Koha HL, Gaob Y, Gongc Z, Leed EJD: Herbal bioactivation: The good, the bad and the ugly. Life Sci 2004;74:935–968.
    1. Potocnjak I, Skoda M, Pernjak-Pugel E, Pavletic Per M, Domitrovic R: Oral administration of oleuropein attenuates cisplatin-induced acute renal injury in mice through inhibition of ERK signaling. Mol Nutr Food Res 2016;60:530–541.
    1. Sun M, Tang Y, Ding T, Liu M, Wang X: Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship. Phytomedicine 2015;22:56–65.
    1. Kiefer D, Pantuso T: Panax ginseng. Am Fam Physician 2003;68:1539–1542.
    1. Ramanathan MR, Penzak SR: Pharmacokinetic drug interactions with Panax ginseng. Eur J Drug Metab Pharmacokinet 2017;42:545–557.
    1. Yokotani K, Chiba T, Sato Y, Nakanishi T, Murata M, Umegaki K: Effect of three herbal extracts on cytochrome P450 and possibility of interaction with drugs [in Japanese]. Shokuhin Eiseigaku Zasshi 2013;54:56–64.
    1. Anderson GD, Rosito G, Mohustsy MA, Elmer GW: Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43:643–648.
    1. Fisher AA, Purcell P, Le Couteur DG: Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol 2000;38:63–66.
    1. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MA, Altimiras J: Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res 2009;23:1795–1796.
    1. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 2010;3:1168–1175.
    1. Detampel P, Beck M, Krähenbühl S, Huwyler J: Drug interaction potential of resveratrol. Drug Metab Rev 2012;44:253–265.
    1. Chi YC, Lin SP, Hou YC: A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats. Toxicol Appl Pharmacol 2012;263:315–322.
    1. Xu W, Zhang T, Wang Z, Liu T, Liu Y, Cao Z, Sui Z: Two potent cytochrome P450 2D6 inhibitors found in Rhodiola rosea. Pharmazie 2013;68:974–976.
    1. Hellum BH, Tosse A, Hoybakk K, Thomsen M, Rohloff J, Georg Nilsen O: Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea. Planta Med 2010;76:331–338.
    1. Spanakis M, Vizirianakis IS, Batzias G, Niopas I: Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Pharmacology 2013;91:112–116.
    1. Maniscalco I, Toffol E, Giupponi G, Conca A: The interaction of Rhodiola rosea and antidepressants. A case report [in German]. Neuropsychiatr 2015;29:36–38.
    1. Thu OKF, Spigset O, Hellum B: Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product. Pharmacol Res Perspect 2017;5:e00324.
    1. Thu OK, Spigset O, Nilsen OG, Hellum B: Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol 2016;72:295–300.
    1. Thu OK, Nilsen OG, Hellum B: In vitro inhibition of cytochrome P-450 activities and quantification of constituents in a selection of commercial Rhodiola rosea products. Pharm Biol 2016;54:3249–3256.
    1. Lima CF, Fernandes-Ferreira M, Pereira-Wilson C: Drinking of Salvia officinalis tea increases CCl(4)-induced hepatotoxicity in mice. Food Chem Toxicol 2007;45:456–464.
    1. Schrøder-Aasen T, Molden G, Nilsen OG: In vitro inhibition of CYP3A4 by the multiherbal commercial product Sambucus Force and its main constituents Echinacea purpurea and Sambucus nigra. Phytother Res 2012;26:1606–1613.
    1. Langhammer AJ, Nilsen OG: In vitro inhibition of human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytother Res 2014;28:603–610.
    1. Sato Y, Sasaki T, Takahashi S, Kumagai T, Nagata K: Development of a highly reproducible system to evaluate inhibition of cytochrome P450 3A4 activity by natural medicines. J Pharm Pharm Sci 2015;18:316–327.
    1. Quílez AM, Saenz MT, García MD: Uncaria tomentosa (Willd. ex. Roem. & Schult.) DC. and Eucalyptus globulus Labill. interactions when administered with diazepam. Phytother Res 2012;26:458–461.
    1. López Galera RM, Ribera Pascuet E, Esteban Mur JI, Montoro Ronsano JB, Juárez Giménez JC: Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. Eur J Clin Pharmacol 2008;64:1235–1236.
    1. Müller AC, Kanfer I: Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm Drug Dispos 2011;32:458–470.
    1. Hellum BH, Hu Z, Nilsen OG: The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007;100:23–30.
    1. Zhou S, Chan E, Li SC, Huang M, Chen X, Li X, Zhang Q, Paxton JW: An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004;11:98–104.
    1. Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, Markowitz JS: Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32:1333–1336.
    1. Kelber O, Nieber K, Kraft K: Valerian: No evidence for clinically relevant interactions. Evid Based Complement Alternat Med 2014;2014:879396.
    1. Dalla Corte CL, Fachinetto R, Colle D, Pereira RP, Avila DS, Villarinho JG, Wagner C, Pereira ME, Nogueira CW, Soares FA, Rocha JB: Potentially adverse interactions between haloperidol and valerian. Food Chem Toxicol 2008;46:2369–2375.
    1. Hoban CL, Byard RW, Musgrave IF: Analysis of spontaneous adverse drug reactions to echinacea, valerian, black cohosh and ginkgo in Australia from 2000 to 2015. J Integr Med 2019;17:338–343.
    1. Wilson V, Maulik SK: Herb-drug interactions in neurological disorders: A critical appraisal. Curr Drug Metab 2018;19:443–453.
    1. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA: In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7:265–273.
    1. Lalani S, Poh CL: Flavonoids as antiviral agents for enterovirus A71 (EV-A71). Viruses 2020;12:712.
    1. Mouffouk C, Mouffouk S, Mouffouk S, Hambaba L, Haba H: Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Eur J Pharmacol 2021;891:173759.
    1. Gorla US, Rao GK, Kulandaivelu US, Alavala RR, Panda SP: Lead finding from selected flavonoids with antiviral (SARS-CoV-2) potentials against COVID-19: An in-silico evaluation. Comb Chem High Throughput Screen 2021;24:879–890.
    1. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY: Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22:525–539.
    1. He X, Luan F, Yang Y, Wang Z, Zhao Z, Fang J, Wang M, Zuo M, Li Y: Passiflora edulis: An insight into current researches on phytochemistry and pharmacology. Front Pharmacol 2020;11:617.
    1. National Library of Medicine: Drugs and Lactation Database (LactMed) [Internet]. National Library of Medicine (US), Bethesda, MD, 2006.
    1. Zhang H, Li C, Kwok ST, Zhang QW, Chan SW: A review of the pharmacological effects of the dried root of Polygonum cuspidatum (Hu Zhang) and its constituents. Evid Based Complement Alternat Med 2013;2013:208349.
    1. Khan M, Maryam A, Mehmood T, Zhang Y, Ma T: Enhancing activity of anticancer drugs in multidrug resistant tumors by modulating P-glycoprotein through dietary nutraceuticals. Asian Pac J Cancer Prev 2015;16:6831–6839.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi